checkAd

Emerging Markets Report A Moment for the Mushroom

Nachrichtenquelle: globenewswire
14.04.2021, 17:17  |  1115   |   |   

Core One Labs Looking to Compete in Psylocibin with a Proprietary Offering at a Fraction of Current Market Cost

An Emerging Markets Sponsored Commentary

ORLANDO, Fla., April 14, 2021 (GLOBE NEWSWIRE) -- Regular readers of the Emerging Markets Report are clear as to our affinity for mushrooms and psychedelic based companies. We are firm believers in the treatment possibilities for psylocibin, especially in mental health applications.

And we believe we are in a very important moment for the mushroom. We’ll explain in just a moment but allow us to introduce our newest featured company, Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(FRA:LD62)(WKN:A2P8K3) which in addition to having a truly remarkable, patent pending drug delivery technology which allows for organic molecules to rapidly enter the bloodstream in precise quantities through a thin film oral strip, is also a mushroom play and a mushroom play with a tremendous competitive advantage.

Core One is intent on bringing psychedelic medicines to market through the aforementioned novel delivery systems and psychedelic assisted psychotherapy. The Company intends to further develop and apply the thin film technology to psychedelic compounds, such as psilocybin, which of course, is derived from mushrooms. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

It’s a big footprint in mushrooms and psychedelics in general. And it is happening in what we expect is a transformative moment for mushrooms. Forgive us, but we’ve seen this act before.

Having been students of the market for decades we realized that cannabis was heading toward some version of legalization reasonably early in the last decade. We saw the early signs of popular opinion turning in favor of recreational and medicinal use in some states and knew that legislative changes were afoot. One normally begets the other.

This past month in Washington D.C. a groundbreaking new law, “DC Initiative 81,” which passed overwhelmingly last fall, went into effect. Per the “Entheogenic Plant and Fungus Policy Act of 2020,” natural psychedelics such as magic mushrooms, ayahuasca, and mescaline are effectively decriminalized, making arrests for their possession or use the lowest priority for D.C. police.

Seite 1 von 3
Core One Labs Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Emerging Markets Report A Moment for the Mushroom Core One Labs Looking to Compete in Psylocibin with a Proprietary Offering at a Fraction of Current Market CostAn Emerging Markets Sponsored Commentary ORLANDO, Fla., April 14, 2021 (GLOBE NEWSWIRE) - Regular readers of the Emerging Markets …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel